News

Keflex is approved for treatment of respiratory tract infections caused by S. pneumoniae and S. pyogenes; otitis media due to S. pneumoniae, H. influenzae, and M. catarrhalis; and

The company’s original application for Extina was turned down in the form of a non-approvable letter received in November 2004 due to insufficient clinical data. As a result

In early June, the same authority granted full reimbursement status for this orally available dual endothelin receptor antagonist. Tracleer(r) is being made available in Japan through Actelion’s own

Remoxy is a novel, abuse-resistant form of long-acting oxycodone, which is the active ingredient in popular but prone to abuse pain medication Oxycontin. The double-blind, randomized, multi-center phase

The firm will use OmniComm’s TrialMaster phase I application to collect data at phase I in-patient units. Laboratory data will be imported into the application in an attempt

Hematide is a peptide-based erythropoiesis stimulating agent (ESA) being developed for the treatment of anemia in patients with chronic kidney disease and cancer. Hematide is currently being evaluated

This consolidation is being undertaken to bring the company into compliance with the minimum bid requirements of Nasdaq. Hemosol believes that retaining its Nasdaq listing is of strategic

Preclinical studies using lung cancer cells have demonstrated, for the first time, that mda-7 protein binds to a critical cellular enzyme called PKR. The binding of mda-7 to

Endo’s drug, a bioequivalent version of Purdue’s OxyContin, does not infringe patent protection according to the court ruling. This affirmation allows Endo to launch the tablets in four